For a 115‑lb (≈52‑kg) patient with hemoglobin A1c 11% who can no longer use GLP‑1 receptor agonist, what starting dose of Lantus (insulin glargine) is recommended?

Starting Dose of Lantus for 115-lb Patient with A1c 11%

For this 115-lb (52 kg) patient with A1c 11% transitioning from GLP-1 therapy to Lantus, start with 10 units once daily subcutaneously at the same time each day.

Rationale for Dosing Decision

The 2025 ADA Standards of Care provide clear guidance for basal insulin initiation: start 10 units per day OR 0.1-0.2 units/kg per day 1. The FDA-approved Lantus prescribing information confirms this recommendation, stating "The recommended starting dose of LANTUS in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily" 2.

Dose Calculation Options:

• Fixed dose approach: 10 units daily (recommended starting point)
• Weight-based approach:
  • At 0.1 units/kg: 52 kg × 0.1 = 5.2 units (round to 5 units)
  • At 0.2 units/kg: 52 kg × 0.2 = 10.4 units (round to 10 units)

The 10-unit starting dose is preferred because:

1. It aligns with both guideline recommendations and FDA labeling
2. The A1c of 11% indicates significant hyperglycemia requiring adequate initial dosing
3. At 115 lbs, the weight-based calculation at 0.2 units/kg yields approximately 10 units
4. Starting too conservatively (5 units) may delay glycemic improvement and perpetuate therapeutic inertia

Critical Titration Protocol

After initiating at 10 units, implement this evidence-based titration algorithm 1:

• Set fasting plasma glucose (FPG) goal based on individualized targets (typically 80-130 mg/dL)
• Increase by 2 units every 3 days to reach FPG goal without hypoglycemia
• For hypoglycemia: determine cause; if no clear reason, lower dose by 10-20%
• Reassess every 3-6 months to avoid therapeutic inertia

Important Clinical Considerations

Hypoglycemia Risk Management

Given this patient's low body weight (115 lbs), prescribe glucagon for emergent hypoglycemia 1. The risk is lower when initiating insulin in insulin-naive patients, but vigilance is essential. Educate the patient to recognize and manage hypoglycemia symptoms 2.

Administration Details

• Timing: Once daily at the same time each day (can be any time, but consistency is key) 2
• Injection sites: Rotate within the same region (abdomen, thigh, or deltoid) to reduce lipodystrophy risk 2
• Do NOT mix or dilute Lantus with any other insulin or solution 2
• Do NOT share insulin devices or needles between patients 2

Monitoring Requirements

• Blood glucose monitoring is essential for all patients on insulin therapy 2
• Use fasting plasma glucose values to guide basal insulin titration 1
• Assess adequacy of insulin dose at every visit 1

Special Context: Transitioning from GLP-1

Since this patient is coming off GLP-1 therapy, be aware that:

• Weight gain is likely with insulin therapy (unlike GLP-1 agents) 1
• The A1c of 11% suggests the GLP-1 was insufficient or not optimally used
• Consider whether the patient might benefit from restarting a GLP-1 RA in combination with insulin once access issues resolve, as combination therapy reduces insulin requirements and weight gain 1

Common Pitfalls to Avoid

1. Starting too low (e.g., 5 units) in a patient with A1c 11% delays glycemic improvement
2. Failing to titrate aggressively every 3 days perpetuates therapeutic inertia
3. Not prescribing glucagon in a low-weight patient on insulin
4. Inadequate patient education about hypoglycemia recognition and self-monitoring
5. Forgetting to rotate injection sites, leading to lipodystrophy and erratic absorption

The evidence strongly supports starting at 10 units daily with systematic titration every 3 days based on fasting glucose values, which will safely and effectively bring this patient's A1c toward goal while minimizing hypoglycemia risk 1, 2.